ICAM1 and breast carcinoma: The cellular potency of the GT DcNP, the GT DcNP-LFA1-P (1%), the GT DcNP-LFA1-P (2%), and the GT-free drug combination were tested in 4T1 breast cancer cells, expressing ICAM-1.